Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Merck Millipore, VWR Extend Western European Distribution Agreement

Published: Wednesday, April 09, 2014
Last Updated: Wednesday, April 09, 2014
Bookmark and Share
Provides VWR access to more Merck Millipore products and reagents for chemical and microbiological analysis.

Merck Millipore announced a new non-exclusive, preferred distribution agreement for Western Europe with VWR a global provider of laboratory supplies, equipment and services. The contract includes a range of Merck Millipore products and reagents for chemical and microbiological analysis, which are mainly used in quality control solutions for the pharmaceutical, food and beverage and chemical industries, as well as products for research in the field of organic synthesis and biosciences. 

“The new contract continues an important relationship with one of Merck Millipore’s largest distributors and reinforces our commitment to providing our existing customers easy access to high quality products,” notes Robert Yates, Head of Merck Millipore. “We will give VWR access to more Merck Millipore products and expect with VWR’s wide geographic coverage across Western Europe we will be able to reach a larger customer base.”  

The contract replaces an exclusive chemical distribution agreement between Merck Millipore and VWR covering Western Europe originally signed in 2004. Under the new preferred agreement, Merck Millipore is free to engage with other organizations, but VWR will remain the distributor of choice through December 2018.

"VWR is proud to renew its agreement with Merck Millipore, to provide customers with high quality chemical and analysis products,” said Peter Schuele, President European Lab Business, VWR. “We enable science with our assurance of supply through an excellent logistic infrastructure and our ability to combine the chemical offering with consumables, equipment, instrumentation and our rapidly growing service business. Merck Millipore is a very important part in our chemical portfolio and the high value we can bring to our customer base”. 


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!